Drugs / RPA563
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02655549 | Dec 2015 → Jun 2017 | anthrax infection | Pfenex, Inc | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPA563 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02655549 ↗ |
| Modality | Vaccine | “The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.” NCT02655549 ↗ |
| Route | Intramuscular | “This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of Px563L or RPA563 administered intramuscularly.” NCT02655549 ↗ |